ES2765006T3 - Reducción del receptor soluble de urocinasa en la circulación - Google Patents

Reducción del receptor soluble de urocinasa en la circulación Download PDF

Info

Publication number
ES2765006T3
ES2765006T3 ES12782210T ES12782210T ES2765006T3 ES 2765006 T3 ES2765006 T3 ES 2765006T3 ES 12782210 T ES12782210 T ES 12782210T ES 12782210 T ES12782210 T ES 12782210T ES 2765006 T3 ES2765006 T3 ES 2765006T3
Authority
ES
Spain
Prior art keywords
supar
fsgs
cartridge
blood
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12782210T
Other languages
English (en)
Spanish (es)
Inventor
Jochen Reiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Application granted granted Critical
Publication of ES2765006T3 publication Critical patent/ES2765006T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
ES12782210T 2011-05-09 2012-05-09 Reducción del receptor soluble de urocinasa en la circulación Active ES2765006T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161457665P 2011-05-09 2011-05-09
PCT/US2012/000240 WO2012154218A2 (en) 2011-05-09 2012-05-09 Reducing soluble urokinase receptor in the circulation

Publications (1)

Publication Number Publication Date
ES2765006T3 true ES2765006T3 (es) 2020-06-05

Family

ID=47139854

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12782210T Active ES2765006T3 (es) 2011-05-09 2012-05-09 Reducción del receptor soluble de urocinasa en la circulación

Country Status (5)

Country Link
US (1) US9867923B2 (cg-RX-API-DMAC7.html)
EP (1) EP2707055B1 (cg-RX-API-DMAC7.html)
JP (1) JP6055464B2 (cg-RX-API-DMAC7.html)
ES (1) ES2765006T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012154218A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
WO2012154218A2 (en) 2011-05-09 2012-11-15 The University Of Miami Reducing soluble urokinase receptor in the circulation
JP6438474B2 (ja) * 2013-08-01 2018-12-12 ザ ジェネラル ホスピタル コーポレイション 非グリコシル化suPARバイオマーカー及びその使用
CN103933615B (zh) * 2014-04-08 2015-10-28 华南理工大学 一种用于肾小球滤过膜修复的自组装多孔聚合物膜及其制备方法与应用
WO2017040488A1 (en) * 2015-08-31 2017-03-09 Rush University Medical Center Prediction of kidney disease, severity and related treatment approaches
WO2017053976A1 (en) * 2015-09-25 2017-03-30 The General Hospital Corporation DIAGNOSTIC ASSAYS FOR SUPAR-β3 INTEGRIN DRIVEN KIDNEY DISEASES
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids
JP2022513317A (ja) * 2018-09-28 2022-02-07 ヨッヘン ライザー suPARならびに急性腎傷害の予測および治療
US20230348613A1 (en) * 2020-06-05 2023-11-02 The Regents Of The University Of California Methods and antibodies in treatment of focal segmental glomerulosclerosis (fsgs)
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
JP7553105B2 (ja) * 2021-03-04 2024-09-18 学校法人産業医科大学 巣状分節性糸球体硬化症の発症時期を推定する方法
TWI830166B (zh) 2022-03-08 2024-01-21 國立成功大學 病理切片影像的脂滴分割方法與電腦程式產品
JP2024034246A (ja) * 2022-08-31 2024-03-13 国立大学法人群馬大学 特発性ネフローゼ症候群の検査方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US6794358B1 (en) 1997-03-28 2004-09-21 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
SE0201257D0 (sv) * 2002-04-25 2002-04-25 Medical Invest In Sweden Ab Improved Separation
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
PL1765397T3 (pl) 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20070244046A1 (en) 2006-03-29 2007-10-18 Margarita Gutova Identification and characterization of cancer stem cells and methods of use
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
JP2011503531A (ja) 2007-10-26 2011-01-27 ジェネンテック, インコーポレイテッド ウロキナーゼ型プラスミノーゲン活性化因子(uPA)活性の阻害
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
US20110212083A1 (en) 2008-11-06 2011-09-01 University Of Miami Office Of Technology Transfer Role of soluble upar in the pathogenesis of proteinuric kidney disease
WO2012154218A2 (en) 2011-05-09 2012-11-15 The University Of Miami Reducing soluble urokinase receptor in the circulation

Also Published As

Publication number Publication date
JP6055464B2 (ja) 2016-12-27
EP2707055A4 (en) 2015-04-15
EP2707055B1 (en) 2019-10-23
EP2707055A2 (en) 2014-03-19
WO2012154218A2 (en) 2012-11-15
WO2012154218A3 (en) 2013-01-03
JP2014517750A (ja) 2014-07-24
US9867923B2 (en) 2018-01-16
US20140083945A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
JP6055464B2 (ja) 循環血中の可溶性ウロキナーゼ受容体の低減
Chirivi et al. Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases
US20240209072A1 (en) Method of Reducing Blood Glucose Levels and Inhibiting Secreted aP2
Margutti et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis
US12178857B2 (en) Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
AU2006267097A1 (en) Methods of diagnosing and treating an inflammatory response
JP2005106694A (ja) 敗血症早期検出及び重篤度評価
JP2020505446A (ja) リソソーム蓄積症およびリソソーム蓄積障害を処置するための組成物および方法
El Mdawar et al. The ATP-gated P2X1 ion channel contributes to the severity of antibody-mediated transfusion-related acute lung injury in mice
Yazdani et al. Targeting tubulointerstitial remodeling in proteinuric nephropathy in rats
WO2018046876A1 (en) Treatment of chronic inflammatory disease
US12108745B2 (en) Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment
Segura-Guerrero et al. De novo glomerulonephritis associated with IgA anti-GBM alloantibodies after kidney transplantation in Alport syndrome: A case report with diagnostic implications
Li et al. Case report: Hyperacute rejection of living relative kidney transplantation caused by colony-stimulating factor 2 antibodies
Genere et al. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: a report on its efficacy and safety in two pediatric patients
WO2019077143A1 (en) METHODS AND COMPOSITIONS FOR PREDICTING AND PRECOCUALLY DIAGNOSING A CHRONIC ACTIVE FORM OF ABMR WITH GRAFT GLOMERULOPATHY AND RENAL TRANSPLANT LOSS
US20260023074A1 (en) Doc2b as a biomarker for type 1 and type 2 diabetes
US12523663B2 (en) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
US20190209680A1 (en) Treatment of acute liver failure
US9724412B2 (en) Chymase compositions, antibodies, diagnostics, and therapeutic methods related thereto
Okawa et al. Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report
Gerber CD13 Regulation of Albuminuria in Response to Renal Injury
Gianesello Protein Uptake at Glomerular Level: Possible Involvement of an Endocytic Machinery in Cell Culture and in Patients with Lupus Nephritis
CN119700741A (zh) 大蒜素在预防和治疗川崎病药物中的应用
CN120053654A (zh) 治疗脓毒症急性肾损伤的药物